Zobrazeno 1 - 10
of 19
pro vyhledávání: '"P, B Ottevanger"'
Autor:
Bouke J. Koeneman, Gerty Schreibelt, Mark A. J. Gorris, Simone Hins - de Bree, Harm Westdorp, Petronella B. Ottevanger, I. Jolanda M. de Vries
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundMetastatic endometrial cancer (mEC) continues to have a poor prognosis despite the introduction of several novel therapies including immune checkpoints inhibitors. Dendritic cell (DC) vaccination is known to be a safe immunotherapeutic moda
Externí odkaz:
https://doaj.org/article/ba90a72256674e0e9275079eb7a990e4
Autor:
Phyllis van der Ploeg, Cynthia SE. Hendrikse, Anna MJ. Thijs, Hans M. Westgeest, Huberdina PM. Smedts, M Caroline Vos, Mathilde Jalving, Christianne AR. Lok, Ingrid A. Boere, Maaike APC. van Ham, Petronella B. Ottevanger, Anneke M. Westermann, Constantijne H. Mom, Roy I. Lalisang, Sandrina Lambrechts, Ruud LM. Bekkers, Jurgen MJ. Piek
Publikováno v:
Heliyon, Vol 10, Iss 1, Pp e23170- (2024)
Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular signature. There remains a high unmet need for alter
Externí odkaz:
https://doaj.org/article/ec80d08ac0c84967956ced20e2dd05ff
Autor:
Nienke van de Kruis, Phyllis van der Ploeg, Jody H.C. Wilting, M. Caroline Vos, Anna M.J. Thijs, Joanne de Hullu, Petronella B. Ottevanger, Christianne Lok, Jurgen M.J. Piek
Publikováno v:
Gynecologic Oncology Reports, Vol 42, Iss , Pp 101035- (2022)
Objective: Clinical efficacy of cytostatic anticancer agents can be determined with the progression-free survival (PFS) ratio. This outcome measure compares PFS achieved by a new treatment (PFS2) to the PFS of the most recent treatment on which the p
Externí odkaz:
https://doaj.org/article/81897c8e0e8b4228992aff841b0b5493
Autor:
Mark R Middleton, Winald R Gerritsen, Ian Walters, Licia Rivoltini, Niven Mehra, Jeroen H A Creemers, Carl G Figdor, I Jolanda M de Vries, Uzi Gileadi, Inka Pawlitzky, Konstantina Grosios, Petronella B Ottevanger
Publikováno v:
BMJ Open, Vol 11, Iss 11 (2021)
Introduction The undiminished need for more effective cancer treatments stimulates the development of novel cancer immunotherapy candidates. The archetypical cancer immunotherapy would induce robust, targeted and long-lasting immune responses while s
Externí odkaz:
https://doaj.org/article/99367d590514408180426cfd3671d3b8
Autor:
Jolien M.R. Van der Meer, Paul K.J.D. de Jonge, Anniek B. van der Waart, Alexander C. Geerlings, Jurgen P. Moonen, Jolanda Brummelman, Janne de Klein, Malou C. Vermeulen, Ralph J.A. Maas, Nicolaas P.M. Schaap, Janneke S. Hoogstad-van Evert, Petronella B. Ottevanger, Joop H. Jansen, Willemijn Hobo, Harry Dolstra
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Combining natural killer (NK) cell adoptive transfer with tumor-sensitizing chemotherapy is an attractive approach against recurrent ovarian cancer (OC), as OC is sensitive to NK cell-mediated immunity. Previously, we showed that CD34+ hematopoietic
Externí odkaz:
https://doaj.org/article/619acac2e57b40f7a452e2426b67db92
Autor:
Mathilde van Gerwen, Tineke Vandenbroucke, Magali Verheecke, Kristel Van Calsteren, Michael J. Halaska, Monica Fumagalli, Robert Fruscio, Amarendra Gandhi, Margreet Veening, Lieven Lagae, Petronella B. Ottevanger, Jens-Uwe Voigt, Jorine de Haan, Mina M. Gziri, Charlotte Maggen, Luc Mertens, Gunnar Naulaers, Laurence Claes, Frédéric Amant
Publikováno v:
Data in Brief, Vol 32, Iss , Pp 106209- (2020)
This manuscript is an accompanying resource of the original research article entitled “Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy” and present data that compare the outcome of 6-year-old-children b
Externí odkaz:
https://doaj.org/article/ecaf4b6562bb401b96efc4676818a728
Autor:
Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Niven Mehra, Simone M. Hins-de Bree, Carl G. Figdor, J. Alfred Witjes, Gerty Schreibelt, I. Jolanda M. de Vries, Winald R. Gerritsen, Petronella B. Ottevanger
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
BackgroundMaintaining health-related quality of life (HRQoL) is highly desirable during systemic therapies for patients with castration-resistant prostate cancer (CRPC). Patient-reported outcome measures (PROs) were studied in our phase IIa trial on
Externí odkaz:
https://doaj.org/article/1a4468dd63ae4da4bf9a44f25eee39a1
Autor:
Mark J. A. Rietveld, Esmee J. Peters, Olga Husson, Floortje K. Ploos van Amstel, Y. Kamm, Sieta Sijtsema, Marieke Diepenbroek, Josca Heier, Celine Zoetbrood, Marijke Zielstra, Sylvie D. Lambert, Judith B. Prins, Petronella B. Ottevanger
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-9 (2019)
Abstract Objective To test the psychometric properties of the Dutch 45-item Supportive Care Needs Survey—Partners and Caregivers (SCNS-P&C45-D) among partners of women with breast cancer living in the Netherlands. Methods In this cross-sectional va
Externí odkaz:
https://doaj.org/article/30bda0baa01649c2a8e037d2340663a7
Autor:
Linda J. M. Oostendorp, Petronella B. Ottevanger, A. Rogier T. Donders, Agnes J. van de Wouw, Ivonne J. H. Schoenaker, Tineke J. Smilde, Winette T. A. van der Graaf, Peep F. M. Stalmeier
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 17, Iss 1, Pp 1-14 (2017)
Abstract Background There is increasing recognition of the delicate balance between the modest benefits of palliative chemotherapy and the burden of treatment. Decision aids (DAs) can potentially help patients with advanced cancer with these difficul
Externí odkaz:
https://doaj.org/article/1df614e6a04e434795eb6140d97ab032
Autor:
M J A, Rietveld, J, van der Velden, A M, Westermann, W J, van Driel, G S, Sonke, P O, Witteveen, F K, Ploos van Amstel, L F A G, Massuger, P B, Ottevanger
Publikováno v:
The Netherlands journal of medicine. 78(6)
Combined administration of intravenous (iv) and intraperitoneal (ip) (iv/ip) chemotherapy is an effective adjuvant treatment option after primary debulking surgery (PDS) for advanced ovarian cancer (OC). Increased toxicityand patient burden limit its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ddac366d786e04a4e78386d0ce058519
https://pubmed.ncbi.nlm.nih.gov/33380532
https://pubmed.ncbi.nlm.nih.gov/33380532